CA1075157A - Veterinary composition containing mono-saccharide - Google Patents
Veterinary composition containing mono-saccharideInfo
- Publication number
- CA1075157A CA1075157A CA274,190A CA274190A CA1075157A CA 1075157 A CA1075157 A CA 1075157A CA 274190 A CA274190 A CA 274190A CA 1075157 A CA1075157 A CA 1075157A
- Authority
- CA
- Canada
- Prior art keywords
- composition
- citric acid
- salt
- amino acid
- monosaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
Abstract
ABSTRACT OF THE DISCLOSURE
A veterinary composition comprising 40 to 80%
of an actively absorbed monosaccharide, 7.5 to 30% of an actively absorbed naturally occurring amino acid, and 0.5 to 10% of an agent which is citric acid or a salt thereof;
except that when the agent is a salt of citric acid, then the amino acid represents no more than 13% of the composition; are useful in the treatment of diarrhoea in animals such as calves.
A veterinary composition comprising 40 to 80%
of an actively absorbed monosaccharide, 7.5 to 30% of an actively absorbed naturally occurring amino acid, and 0.5 to 10% of an agent which is citric acid or a salt thereof;
except that when the agent is a salt of citric acid, then the amino acid represents no more than 13% of the composition; are useful in the treatment of diarrhoea in animals such as calves.
Description
~s~
The present inven-tlon relates to veterinary compo~ltions useful for treating diarrhoea (e.g. scours~ in domestic animals and to the use o~ such compositions in the treatment of diarrhoea by rehydration.
A co~mon and highly deb:ilitating disease affecting young domestic animals such a~ cal~es a~d piglets is diarrhoea. Diarrhoea causes ~3evere dehydra-tion which in turn oauses a significant wei~ht loss ln the animal and can in severe cases lead to death. It i3 believed that often the diarrhoea symptoms are caused by a toxin or toxins of bacterial origin so that one method ~or the treatment o~ diarrhoea is the a~ministra-tion of anti-bacterial agentsO Considerable success can be aohieved by using such anti-bacterial agents a~ ampicillin or amoxycillin but th~re are occasions when an alternative therapy i~ required. Recently U.S. Patent No: 3898328 disclo&ed that compos.itions containing glycine, glucose and electrolyte~ are e~ectlve in the treatment of scours by bringing about a rehydration of the scouring animal.
A dis~inct olass of compositions has ~ow been disco~ered which combine e~fectlvene~s in diarrhoea (e.g. scours) treatment with ease o~ formulationl palatability and use~ul st~bility~
Accordi~gly the present inventio~ proYides a veterinary compo~ition comprising 40 to 80~ of an actively absvrbed mono-saccharide~ 7.5 to 30% of an act~ely absorbed naturally occurring amino acid9 z_ :
:
::
: ~ ::: : :
07S~S7 an~ 0.5 to 10% of an agent which is citric acid or a salt thereo~; except that when the agent is a salt o~
citric acid, then the amino acid represents no more than 1~% o~ the composition.
All percentages used he:re~n are calculated on a weight/total weight basis.
Active absorption (or active transport~ is well known to the skilled man, as ~are the monosaccharldeæ and amino acids which are actively absor~ed. I~ this regard the reader is referred to standard text books such as ~Medicinal Phy~iology~ by ~uyton (published by W.~. Saunders and Company) 4th Edition pages 769 to 771 Of course whether or not a particular mono~accharide or a~ino acid is actively absorbed may also readily be de-termined by experiment as ~or example described in Wilson T.H. 1962 Intestinal Absorption ~Sau~ders, Philadelphia).
To be actively ab~orbed, mo~saccharides must have (a) at least six carbon atoms in their chairl (b) a D-pyranose ring structure and (c) an intact :hydroxyl group at car~on 2. Thu~ suitable examples o~
monosaccharides ~or use in this invention include the ; naturally occurring D~pyranoses such as glucose and galactose. Other examples of suitable monosaccharides include naturally occ~rring D-pyranoses that have been chemically modified whilst retaining the necessary structural fea-tures ~a~, ~b) and (c). Exam~les of such . . . . , . -. .
- ' :
hO7S~LS7 modi~ied monosaccharid0s include C2 7 acylated and ~1 4 alkylated derivatives, such as acetyl~ methyl, ethyl and n- and iso-propyl derivatives. 5peci~ic examples include ~-methyl glucoside, ~-O-methyl glucose and 6-deoxygalactose.
Pre~erably the monosaccharide wlll be glucose or galactose. The monosaccharide of choice for use in this invention is glucose (e.g. de.xtrose). The stabllity o~ the resul-tant composition is enhanced i~ the mono-saccharide used is anhydrous, ~or example anhydrous glucose.
Suitable examples o~ actively ab~orbed naturally occurri.ng amino acids include neutral amino acids such as glycine and ala~ine and basic amino acids such as arginine. Preferably the amino acid is glycine.
The veterinary compo~itions of the i~vention will normally co~tain 10 to ?5% electrolytes. Suitable electrol~tes for such inclusion include ~alt.s containing io~s such as sodiwm, potassium, calcium~ ma~esium~
chlorideJ phosphate, gluconate, sulphate, blcarbonate,Carbnate and the like. Other favoured electrol~tes f'or inclusion in the compositions include potassll~ dihydrogen pho~phate, dipotassium hydrogen phosphate, tripotassium phosphate1 potassium chloride and the like, with potassium dihydrogen phosphate being particularl~J suitable.
~;
4_ .. . .. . . . . . .
- . ; . . : . .. . . . .
~75~5~
One particularly preferred electrolyte f'or inclusion in the composition of the invention is sodium chlor:ide which T.^rill normally account for 7 to 20% o~
the composition, for exiample :10-- 16% of the composition.
The monosaccharide is defined as representing 40 to 80% of the composition. More isiuitably it will represent 50 to 75%, for example 60 to 75% of ~he composition. Often the mo~osaccharide will represent at leai~it 65% o~ the compositlon~ Similarly while the iamino acid in the compositio~ can repre.sent 7.5 to ZO% of the composition~ more suitably it wlll represent 7.5 to 20~
of the composition~ for exi~mple 8 to 15% of the composition~
8 to 12% has been found to be a particularly isuitable inclusion ri~nge ~or the iamino acid.
One suitable veterinary composltion comprises 40 to 80~ o~ an actively absorbed monosaccharide9 7.5 to 30% of i~n acti~ely absorbed naturally occurring amino acid, and 0.5 to 10% o~ citric acid.
The citric acid represents 0.5 to 10% of this composition. More suitably the citric acid will represent 0.5 to 5%, preferably 0.5 to 2%, ~or exiample 0.6 to 1.2yo o~ the composition. Often the composition will contain both citric acid and a salt thereof9 bu~ com~ined the citric acid and the salt thereof will not represent more than 10% of' ~he composition. Suitable exiamples of such salts include sodium or potassium salts such as mono-, - . . .. .. . . . .
-. ~. . j , ; , ~ : . ~ . . .
, 1~75~57 di- or trl-sodium, or mono-, dl- or tri-potassium citrate. O~ten the composition wi.ll include 0.1 to 5% o~ a salt of citric acid, more 3uitably 0.1 to 0.5%
of such a salti From the afores~id it w.ill be seen that one part-icularly suitable veterinary composition of the inventlon will comprise 50 to 75% glucose or galactose7 7.5 to 20%
o~ glycine, alanine or arginine, 0~ 5 to 10% citric acid and 7 to 20% o~ sodium chloride.
More sultably, such compositions will contaln 0.5 to 5% citrio acid, and 0.1 to 5% of a ~alt o~ oitric acid.
Preferably sueh compositions contain glucose as the mono~accharide and glycine as the amino acid.
Thu~ a particularly pre~erred composition of the l~vention compri~es 60 to 75% glucose, 8 to 15% glycine, 0.5 to ~% citric acid, 0.1 to 0.5% of a 3alt of citrlc acid, and 10 to 16% sodium chloride. Such compos~ Itions often i~clude 5 to 10% OI potas~ium ~ihydrogen pho~phate.
A second suitable ~eteri~ary composition comprise~
40 to 80~ of an actively absorbed monosaccharide~ 7.5 to 13% oP an actively absorbed naturally occurri~g amino acid9 : ' ' ' `
. - . ; , . . . .
, ,, , . :, ., . , ,: ~ . :
. ~ , . . ..
1~5~5'7 and 0.5 to 10% o~ a citrate salt~
The citrate salt represents 0.5 to 10% of this composition. More suitably the salt will represent 0.5 to 5%, pre~erably 0.5 to 2%, .for example 0~6 to 1.2%
of the compositlon. Suitable examples of citrate saltq include sodium or potassium salts such as mono-~ di- or tri-~odium, or mono-, di~ or tri-potassium citrate.
From the a~oresa~d lt w.Lll be ~een that one particularly suitable veterinary composition o~ the in-vention will comprise 50 to 75~0 glucosc or galactose, 7.5 to 13% of glycine, alanine or arginine, 0.5 to 10%
of a citra~e salt and 7 to 20% of sodium chloride.
More suitably, such compositions will contain 0.5 to 5% of a salt of citric acid.
~referably suoh compositions contain glUC08e as the mono-saccharide and glycine a~ the amino acid.
Thus a particularly preferred compositicn of the invention comprises 60 to 75% glucose, 8 to 12% glycine, 0.5 to 2% of a salt of citric acid, and 10 t:o 16% sodium chloride, Such compositions often include 5 to 10% of potassium dihydrogen phosphateO
These compositions suitably contain at least 65%
monosaccharide .
If desired the compositions of this invention can contain other substances such as vitamins, minerals, buffers9 : excipients or the liXe in co~ventional manner.
; - 7 ~
. ~ , . .
~ ' ', .
~753LS7 In g~neral the compos.itions of this in~en-tion will be in the form o~ a dry pol~der ~or e~ample on~ which is readily soluble in water. Ho~ever i~ an ~lternat~ve aspect the compositions of this inve:ntlon l,rill comprlse a~ aqueous solutio~ containing dissolved therein the previously defined solutes in the previously defined relative proportions.
The powders of this invention may be prepared by mixing togeth~r the indlvldua:l components ln conventional manner. Once mixed the compo~ition may be put into sachets or other conve~tional containers~ I~ is frequently advantageous to separate the monosaccharide component from the other components of the composition. Thi~ can be ef~ected by using double sachets or other double con-tainers. In ~uch cases components other than the mono-sacch~ride c~n be.mixed ~nd filled into o~e half of the double sachet and the monosaccharide can be ~illed in~o the o~her hal~ of the double sachet. In such form the compositions of ths i~vention ha~e bee~ ~o~d ~o be particularly stable.
The compo~ition of the invention will .normally ~e adminis-tered to the diarrhoeic animal in the form o~ an . aqueous solution, by the oral route. Such solutions may : for example contain 20 to 45 g./litre of the composition, suitably 25 to 35 g./litre, for example 30g./litre.
In-general calves will be adminis~ered from 2 to a~ l~ast 4 litre~ per day o~-~uc~- solutions while p~glet~ wi71 ~ormally be ; adminlstared from a ~uarter to a one litre p~r dayO
: 8 : . ~ ' '' ' . ~ , . : , . .
~ ~ 7 S~ ~ 7 The sGlutions may be administered ad 11bitum or in two to ~our or more equal doses per day or by any other ~imilar conventional regime.
From a further aspect this inventlon provides a method of treat~ng diarrhoea 1n domestic animals which method comprises administering to the animal sufferin~ from diarr~oea a liquid composition of thi~
inYention.
It will be realised that in the treatment of severely scouring an~mals anti-bacterial agents may be administered in con~unctlon wlth the composition~ o~ the inventionO Examples of suitable anti-bacterial agents for such use include ampicillin, amoxycillin ~nd tetracycline~.
me ~killed man will realise that the effective absorption properties found with the liquid compositions of the invention wlll enable them to be used with advantage whenever liquid absorption by animals i~ a problem. For example the compositions mayb~3 used in ?O treating the general dehydration found in p~t-operative condltions in animals such as dogs and cats~ ~hey may al~o be administered with advantage to stres~ed animals, such ~s recently purchased calves ~nd the like. It is howe~er believed that the composit~ons o~ the in~enti~n ~: 25 will be o~ the greatest use in the treatment of diarrhoea ; ln calves.
~ The following Examples illustrate the invention:
;~
. ~ . :, ~ . .
: ~ , . . .
: ~'" `. ~ ' ' ~. . - : . , .
75~La5 7 1 kg. o~ the ~ollowlng composltio~ was prepared by mixing together the lngred.ients in dry powder ~orm:-Glycine ~ 10.3%
D~trose~nhydrous) : 67.6 50dium Chlorlde : 14.3 Potas~ium Dihydrogen . 6 Phosphate Citric Acid : 0.8 Tri-potassium Citrate : O,2 60g. o~ the composition was then dissolved ln
The present inven-tlon relates to veterinary compo~ltions useful for treating diarrhoea (e.g. scours~ in domestic animals and to the use o~ such compositions in the treatment of diarrhoea by rehydration.
A co~mon and highly deb:ilitating disease affecting young domestic animals such a~ cal~es a~d piglets is diarrhoea. Diarrhoea causes ~3evere dehydra-tion which in turn oauses a significant wei~ht loss ln the animal and can in severe cases lead to death. It i3 believed that often the diarrhoea symptoms are caused by a toxin or toxins of bacterial origin so that one method ~or the treatment o~ diarrhoea is the a~ministra-tion of anti-bacterial agentsO Considerable success can be aohieved by using such anti-bacterial agents a~ ampicillin or amoxycillin but th~re are occasions when an alternative therapy i~ required. Recently U.S. Patent No: 3898328 disclo&ed that compos.itions containing glycine, glucose and electrolyte~ are e~ectlve in the treatment of scours by bringing about a rehydration of the scouring animal.
A dis~inct olass of compositions has ~ow been disco~ered which combine e~fectlvene~s in diarrhoea (e.g. scours) treatment with ease o~ formulationl palatability and use~ul st~bility~
Accordi~gly the present inventio~ proYides a veterinary compo~ition comprising 40 to 80~ of an actively absvrbed mono-saccharide~ 7.5 to 30% of an act~ely absorbed naturally occurring amino acid9 z_ :
:
::
: ~ ::: : :
07S~S7 an~ 0.5 to 10% of an agent which is citric acid or a salt thereo~; except that when the agent is a salt o~
citric acid, then the amino acid represents no more than 1~% o~ the composition.
All percentages used he:re~n are calculated on a weight/total weight basis.
Active absorption (or active transport~ is well known to the skilled man, as ~are the monosaccharldeæ and amino acids which are actively absor~ed. I~ this regard the reader is referred to standard text books such as ~Medicinal Phy~iology~ by ~uyton (published by W.~. Saunders and Company) 4th Edition pages 769 to 771 Of course whether or not a particular mono~accharide or a~ino acid is actively absorbed may also readily be de-termined by experiment as ~or example described in Wilson T.H. 1962 Intestinal Absorption ~Sau~ders, Philadelphia).
To be actively ab~orbed, mo~saccharides must have (a) at least six carbon atoms in their chairl (b) a D-pyranose ring structure and (c) an intact :hydroxyl group at car~on 2. Thu~ suitable examples o~
monosaccharides ~or use in this invention include the ; naturally occurring D~pyranoses such as glucose and galactose. Other examples of suitable monosaccharides include naturally occ~rring D-pyranoses that have been chemically modified whilst retaining the necessary structural fea-tures ~a~, ~b) and (c). Exam~les of such . . . . , . -. .
- ' :
hO7S~LS7 modi~ied monosaccharid0s include C2 7 acylated and ~1 4 alkylated derivatives, such as acetyl~ methyl, ethyl and n- and iso-propyl derivatives. 5peci~ic examples include ~-methyl glucoside, ~-O-methyl glucose and 6-deoxygalactose.
Pre~erably the monosaccharide wlll be glucose or galactose. The monosaccharide of choice for use in this invention is glucose (e.g. de.xtrose). The stabllity o~ the resul-tant composition is enhanced i~ the mono-saccharide used is anhydrous, ~or example anhydrous glucose.
Suitable examples o~ actively ab~orbed naturally occurri.ng amino acids include neutral amino acids such as glycine and ala~ine and basic amino acids such as arginine. Preferably the amino acid is glycine.
The veterinary compo~itions of the i~vention will normally co~tain 10 to ?5% electrolytes. Suitable electrol~tes for such inclusion include ~alt.s containing io~s such as sodiwm, potassium, calcium~ ma~esium~
chlorideJ phosphate, gluconate, sulphate, blcarbonate,Carbnate and the like. Other favoured electrol~tes f'or inclusion in the compositions include potassll~ dihydrogen pho~phate, dipotassium hydrogen phosphate, tripotassium phosphate1 potassium chloride and the like, with potassium dihydrogen phosphate being particularl~J suitable.
~;
4_ .. . .. . . . . . .
- . ; . . : . .. . . . .
~75~5~
One particularly preferred electrolyte f'or inclusion in the composition of the invention is sodium chlor:ide which T.^rill normally account for 7 to 20% o~
the composition, for exiample :10-- 16% of the composition.
The monosaccharide is defined as representing 40 to 80% of the composition. More isiuitably it will represent 50 to 75%, for example 60 to 75% of ~he composition. Often the mo~osaccharide will represent at leai~it 65% o~ the compositlon~ Similarly while the iamino acid in the compositio~ can repre.sent 7.5 to ZO% of the composition~ more suitably it wlll represent 7.5 to 20~
of the composition~ for exi~mple 8 to 15% of the composition~
8 to 12% has been found to be a particularly isuitable inclusion ri~nge ~or the iamino acid.
One suitable veterinary composltion comprises 40 to 80~ o~ an actively absorbed monosaccharide9 7.5 to 30% of i~n acti~ely absorbed naturally occurring amino acid, and 0.5 to 10% o~ citric acid.
The citric acid represents 0.5 to 10% of this composition. More suitably the citric acid will represent 0.5 to 5%, preferably 0.5 to 2%, ~or exiample 0.6 to 1.2yo o~ the composition. Often the composition will contain both citric acid and a salt thereof9 bu~ com~ined the citric acid and the salt thereof will not represent more than 10% of' ~he composition. Suitable exiamples of such salts include sodium or potassium salts such as mono-, - . . .. .. . . . .
-. ~. . j , ; , ~ : . ~ . . .
, 1~75~57 di- or trl-sodium, or mono-, dl- or tri-potassium citrate. O~ten the composition wi.ll include 0.1 to 5% o~ a salt of citric acid, more 3uitably 0.1 to 0.5%
of such a salti From the afores~id it w.ill be seen that one part-icularly suitable veterinary composition of the inventlon will comprise 50 to 75% glucose or galactose7 7.5 to 20%
o~ glycine, alanine or arginine, 0~ 5 to 10% citric acid and 7 to 20% o~ sodium chloride.
More sultably, such compositions will contaln 0.5 to 5% citrio acid, and 0.1 to 5% of a ~alt o~ oitric acid.
Preferably sueh compositions contain glucose as the mono~accharide and glycine as the amino acid.
Thu~ a particularly pre~erred composition of the l~vention compri~es 60 to 75% glucose, 8 to 15% glycine, 0.5 to ~% citric acid, 0.1 to 0.5% of a 3alt of citrlc acid, and 10 to 16% sodium chloride. Such compos~ Itions often i~clude 5 to 10% OI potas~ium ~ihydrogen pho~phate.
A second suitable ~eteri~ary composition comprise~
40 to 80~ of an actively absorbed monosaccharide~ 7.5 to 13% oP an actively absorbed naturally occurri~g amino acid9 : ' ' ' `
. - . ; , . . . .
, ,, , . :, ., . , ,: ~ . :
. ~ , . . ..
1~5~5'7 and 0.5 to 10% o~ a citrate salt~
The citrate salt represents 0.5 to 10% of this composition. More suitably the salt will represent 0.5 to 5%, pre~erably 0.5 to 2%, .for example 0~6 to 1.2%
of the compositlon. Suitable examples of citrate saltq include sodium or potassium salts such as mono-~ di- or tri-~odium, or mono-, di~ or tri-potassium citrate.
From the a~oresa~d lt w.Lll be ~een that one particularly suitable veterinary composition o~ the in-vention will comprise 50 to 75~0 glucosc or galactose, 7.5 to 13% of glycine, alanine or arginine, 0.5 to 10%
of a citra~e salt and 7 to 20% of sodium chloride.
More suitably, such compositions will contain 0.5 to 5% of a salt of citric acid.
~referably suoh compositions contain glUC08e as the mono-saccharide and glycine a~ the amino acid.
Thus a particularly preferred compositicn of the invention comprises 60 to 75% glucose, 8 to 12% glycine, 0.5 to 2% of a salt of citric acid, and 10 t:o 16% sodium chloride, Such compositions often include 5 to 10% of potassium dihydrogen phosphateO
These compositions suitably contain at least 65%
monosaccharide .
If desired the compositions of this invention can contain other substances such as vitamins, minerals, buffers9 : excipients or the liXe in co~ventional manner.
; - 7 ~
. ~ , . .
~ ' ', .
~753LS7 In g~neral the compos.itions of this in~en-tion will be in the form o~ a dry pol~der ~or e~ample on~ which is readily soluble in water. Ho~ever i~ an ~lternat~ve aspect the compositions of this inve:ntlon l,rill comprlse a~ aqueous solutio~ containing dissolved therein the previously defined solutes in the previously defined relative proportions.
The powders of this invention may be prepared by mixing togeth~r the indlvldua:l components ln conventional manner. Once mixed the compo~ition may be put into sachets or other conve~tional containers~ I~ is frequently advantageous to separate the monosaccharide component from the other components of the composition. Thi~ can be ef~ected by using double sachets or other double con-tainers. In ~uch cases components other than the mono-sacch~ride c~n be.mixed ~nd filled into o~e half of the double sachet and the monosaccharide can be ~illed in~o the o~her hal~ of the double sachet. In such form the compositions of ths i~vention ha~e bee~ ~o~d ~o be particularly stable.
The compo~ition of the invention will .normally ~e adminis-tered to the diarrhoeic animal in the form o~ an . aqueous solution, by the oral route. Such solutions may : for example contain 20 to 45 g./litre of the composition, suitably 25 to 35 g./litre, for example 30g./litre.
In-general calves will be adminis~ered from 2 to a~ l~ast 4 litre~ per day o~-~uc~- solutions while p~glet~ wi71 ~ormally be ; adminlstared from a ~uarter to a one litre p~r dayO
: 8 : . ~ ' '' ' . ~ , . : , . .
~ ~ 7 S~ ~ 7 The sGlutions may be administered ad 11bitum or in two to ~our or more equal doses per day or by any other ~imilar conventional regime.
From a further aspect this inventlon provides a method of treat~ng diarrhoea 1n domestic animals which method comprises administering to the animal sufferin~ from diarr~oea a liquid composition of thi~
inYention.
It will be realised that in the treatment of severely scouring an~mals anti-bacterial agents may be administered in con~unctlon wlth the composition~ o~ the inventionO Examples of suitable anti-bacterial agents for such use include ampicillin, amoxycillin ~nd tetracycline~.
me ~killed man will realise that the effective absorption properties found with the liquid compositions of the invention wlll enable them to be used with advantage whenever liquid absorption by animals i~ a problem. For example the compositions mayb~3 used in ?O treating the general dehydration found in p~t-operative condltions in animals such as dogs and cats~ ~hey may al~o be administered with advantage to stres~ed animals, such ~s recently purchased calves ~nd the like. It is howe~er believed that the composit~ons o~ the in~enti~n ~: 25 will be o~ the greatest use in the treatment of diarrhoea ; ln calves.
~ The following Examples illustrate the invention:
;~
. ~ . :, ~ . .
: ~ , . . .
: ~'" `. ~ ' ' ~. . - : . , .
75~La5 7 1 kg. o~ the ~ollowlng composltio~ was prepared by mixing together the lngred.ients in dry powder ~orm:-Glycine ~ 10.3%
D~trose~nhydrous) : 67.6 50dium Chlorlde : 14.3 Potas~ium Dihydrogen . 6 Phosphate Citric Acid : 0.8 Tri-potassium Citrate : O,2 60g. o~ the composition was then dissolved ln
2 litre~ o~ water.
. . ~ , ., - . . , ,: , -: . . . . . . . . .. .
3L~tYS~ 7 The :Eollowring composition was prepared by a method analogou~ to that of Ex~mple l:
Glycine : 10%
Dextrose (~hydrous) : 72 Sodium Chloride : lO
Cltric Acid : 5 Tri-potassium Citra~e: 3 60g. of the compositlo;a was then dissolved in litres oî water.
.
.
i` ~
:::
, . . . .
. ' ,', ` '' ~' : ' ~'. '., .'' ' . '. , ',, ', ' ' ' ' iL(~'7S~i7 EXAM
- For storage, the composition according to Example 1 was prepared in the same manner, but the dextrose (676g.) was filled into one container and the remaining ingredient~
(324g.) were filled into a second container.
-:
~ ~ ' , ~ ......... . . . . ..... .... ... ........... .... .. .. . . . ...
:, . . . .. .
~ ~ S~5'7 By way of comparison, acute absorption studies were carried out on the composition o~ Example 1, hereinafter referred to as composition J, and a composition X:
w/w ~
Sodium Chloride -~1 h Calcium Gluconate 2.2 Magnesium Sul~ate 0.6 Monopotassium Phosphate 8.7 Glycine 21.2 Dextrose, anhydrous55.7 Composition X ~orresponds to Form~-ation 1 of Example 2 of US Patent No: 3898328. Composition J and Composition X
were made up into isotonic aqueou~ solutions of approximately 300 mill~osmoles/kg.. Isotonic Saline was used as a control.
The method used was to anae~theti~e sc,ouring calves, and identify point~ along the small intestine a-t about 10%, 30%, 50%, 70% and 90% of the distance :~rom the pyloric sphi~cter to the ileocaecal valve~ ~t each o~ these points, ~ series o~ short lengths of intestine were isolated by ligatures, Solutions under i~ve~-tigation were i~eoted into the e loops and the water mo~ement followed by measuring changes in phenol red concentration.
The results obt~lned were as shown in the Table below:-~ ~3 ~
.. . . . ..
~75~L~7 _~___ _ % Distance Water Pyloric Absorbed Sphincter Composltion ml/cm/30 min Stan.
to the Ileo- I (mean of De~.
caecal valve I seven tests) ~ __ _ Saline - 0.083 ~0.023 X I - 0.016 ~0.019 J I ~ 0.078 +0.012 ~ ~ ~ ~ , _ Saline ~ 0.007 +0.020 ~ + Q.036 +0.024 J ~ 0.070 +0.022 ,_~
Saline 0.0~1 ~0.020 X 0.07g +0.032 J 0.146 ~0.040 ~ _ Salin~ 0.108 ~0.027 X 0.0~5 +0.036 0.~2~ ~0.007 _ Saline 0.099 ~0.038 X ~.129 ~0.~2 : J 0.1~5 ~0.034 . ~ ~ ~ ~
These results show that absorption o~ water hy the scouring calves ~rom com~osition J is significantly more rapid than from saline (p~0.01) or ~rom composition X
(pC 0.05, analysis of variance). : -~ , - ~ . ............ , . : : . - .
. . ~ . .................. . . . . .
' ~ ' ' '. '' ~ , . ' ' ~7~i7 1 kg. o~ the following c:omposition was prepared by mixing together the ingredi.ents in dry powder form:~-Glycine : 10.3%
Dextrose (anhydrous) : 67.6 Sodium Chloride : 14.3 Potassium Dihydrogen . ~ 8 Phospha-te Tri~pota~sium Citrate : 1.O
60g. o~ the composition was then dissol~ed in 2 litres o~ water.
` ::
, ~
'' ' ~ .'' " ' '" ' ".'' ~, ' ' `~ ' . '.' ' '. ' , ' " ' ' ' ' ' , , ' . , .
IL~D7 EX~MPLE 6 _._ The following composition was prepared by a method analogous to that o~ xample 5:-Glycille : 10%
De~trose ~anhydrous ): 72 Sodium Chloride : 10 Tri-pota~sium Citrate: 8 ~ Og. o~ this composition was then dissolved in 2 litres o~ water.
: ~
~; : 16 , : . ., - . . . . .
. .
., .
:1~75~5t7
. . ~ , ., - . . , ,: , -: . . . . . . . . .. .
3L~tYS~ 7 The :Eollowring composition was prepared by a method analogou~ to that of Ex~mple l:
Glycine : 10%
Dextrose (~hydrous) : 72 Sodium Chloride : lO
Cltric Acid : 5 Tri-potassium Citra~e: 3 60g. of the compositlo;a was then dissolved in litres oî water.
.
.
i` ~
:::
, . . . .
. ' ,', ` '' ~' : ' ~'. '., .'' ' . '. , ',, ', ' ' ' ' iL(~'7S~i7 EXAM
- For storage, the composition according to Example 1 was prepared in the same manner, but the dextrose (676g.) was filled into one container and the remaining ingredient~
(324g.) were filled into a second container.
-:
~ ~ ' , ~ ......... . . . . ..... .... ... ........... .... .. .. . . . ...
:, . . . .. .
~ ~ S~5'7 By way of comparison, acute absorption studies were carried out on the composition o~ Example 1, hereinafter referred to as composition J, and a composition X:
w/w ~
Sodium Chloride -~1 h Calcium Gluconate 2.2 Magnesium Sul~ate 0.6 Monopotassium Phosphate 8.7 Glycine 21.2 Dextrose, anhydrous55.7 Composition X ~orresponds to Form~-ation 1 of Example 2 of US Patent No: 3898328. Composition J and Composition X
were made up into isotonic aqueou~ solutions of approximately 300 mill~osmoles/kg.. Isotonic Saline was used as a control.
The method used was to anae~theti~e sc,ouring calves, and identify point~ along the small intestine a-t about 10%, 30%, 50%, 70% and 90% of the distance :~rom the pyloric sphi~cter to the ileocaecal valve~ ~t each o~ these points, ~ series o~ short lengths of intestine were isolated by ligatures, Solutions under i~ve~-tigation were i~eoted into the e loops and the water mo~ement followed by measuring changes in phenol red concentration.
The results obt~lned were as shown in the Table below:-~ ~3 ~
.. . . . ..
~75~L~7 _~___ _ % Distance Water Pyloric Absorbed Sphincter Composltion ml/cm/30 min Stan.
to the Ileo- I (mean of De~.
caecal valve I seven tests) ~ __ _ Saline - 0.083 ~0.023 X I - 0.016 ~0.019 J I ~ 0.078 +0.012 ~ ~ ~ ~ , _ Saline ~ 0.007 +0.020 ~ + Q.036 +0.024 J ~ 0.070 +0.022 ,_~
Saline 0.0~1 ~0.020 X 0.07g +0.032 J 0.146 ~0.040 ~ _ Salin~ 0.108 ~0.027 X 0.0~5 +0.036 0.~2~ ~0.007 _ Saline 0.099 ~0.038 X ~.129 ~0.~2 : J 0.1~5 ~0.034 . ~ ~ ~ ~
These results show that absorption o~ water hy the scouring calves ~rom com~osition J is significantly more rapid than from saline (p~0.01) or ~rom composition X
(pC 0.05, analysis of variance). : -~ , - ~ . ............ , . : : . - .
. . ~ . .................. . . . . .
' ~ ' ' '. '' ~ , . ' ' ~7~i7 1 kg. o~ the following c:omposition was prepared by mixing together the ingredi.ents in dry powder form:~-Glycine : 10.3%
Dextrose (anhydrous) : 67.6 Sodium Chloride : 14.3 Potassium Dihydrogen . ~ 8 Phospha-te Tri~pota~sium Citrate : 1.O
60g. o~ the composition was then dissol~ed in 2 litres o~ water.
` ::
, ~
'' ' ~ .'' " ' '" ' ".'' ~, ' ' `~ ' . '.' ' '. ' , ' " ' ' ' ' ' , , ' . , .
IL~D7 EX~MPLE 6 _._ The following composition was prepared by a method analogous to that o~ xample 5:-Glycille : 10%
De~trose ~anhydrous ): 72 Sodium Chloride : 10 Tri-pota~sium Citrate: 8 ~ Og. o~ this composition was then dissolved in 2 litres o~ water.
: ~
~; : 16 , : . ., - . . . . .
. .
., .
:1~75~5t7
3~Z
For storage, the compo~:L~ion according to Example 5 was prepared in the same manner, bu-t the dextrose (676g.3 was filled into one container and the ~emainlng ingrodients ~324 g.) were filled into a second container.
E _ To 60g~ o~ a c~mposition prepared according to Example 1 was added 400mg. o~ amoxyolllin.
~ .
lkg. of ~ach o~ the following compo~itions D, I and C
were prepared by mixing together the ingredie~ts in dry powder ~orm:
D I G
% % ~;
NaCl 31~33 14.8 15 Gluoose 50.5 66.87 61 Glycine 10.11 9.39 12 c~triG acid 3~00 19 33 3 K3 citrate 5006 1.23 3 KH2P~4 ~ 8 6 ::
:. . - , , , -. . . .
.
~ . . .. ~ , . . . . ..
.. , : . , .... , :, , . . : .
. . .
.
For storage, the compo~:L~ion according to Example 5 was prepared in the same manner, bu-t the dextrose (676g.3 was filled into one container and the ~emainlng ingrodients ~324 g.) were filled into a second container.
E _ To 60g~ o~ a c~mposition prepared according to Example 1 was added 400mg. o~ amoxyolllin.
~ .
lkg. of ~ach o~ the following compo~itions D, I and C
were prepared by mixing together the ingredie~ts in dry powder ~orm:
D I G
% % ~;
NaCl 31~33 14.8 15 Gluoose 50.5 66.87 61 Glycine 10.11 9.39 12 c~triG acid 3~00 19 33 3 K3 citrate 5006 1.23 3 KH2P~4 ~ 8 6 ::
:. . - , , , -. . . .
.
~ . . .. ~ , . . . . ..
.. , : . , .... , :, , . . : .
. . .
.
Claims (22)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A veterinary composition comprising 40 to 80% of an actively absorbed mono-saccharide, 7.5 to 30% of an actively absorbed naturally occurring amino acid, and 0.5 to 10% of an agent which is citric acid or a salt thereof; except that when the agent is a salt of citric acid, then the amino acid represents no more than 13%
of the composition.
of the composition.
2. A veterinary composition as claimed in claim 1, comprising 40 to 80% of an actively absorbed monosaccharide, 7.5 to 30% of an actively absorbed naturally occurring amino acid, and 0.5 to 10% of citric acid.
3. A composition as claimed in claim 2, wherein the monosaccharide is glucose.
4. A composition as claimed in claim 2, wherein the monosaccharide represents at least 65% of the composition.
5. A composition as claimed in claim 2, wherein the amino acid is glycine.
6. A composition as claimed in claim 2, 3 or 5, wherein the amino acid represents 8 to 12% of the composition.
7. A composition as claimed in any one of claims 2, 3 or 5, additionally comprising 7 to 20% sodium chloride.
8. A composition as claimed in claim 2, wherein the citric acid represents 0.5 to 5%
of the composition.
of the composition.
9. A composition as claimed in claim 8, additionally comprising 0.1 to 5% of a salt of citric acid.
10. A composition as claimed in claim 2, comprising 60 to 75% glucose, 8 to 15% glycine, 0.5 to 2% citric acid, 0.1 to 0.5% of a salt of citric acid, and 10 to 16% sodium chloride.
11, A composition as claimed in claim 1, additionally comprising an antibacterial agent.
12. A composition as claimed in claim 1, in aqueous solution.
13. A veterinary composition as claimed in claim 1, comprising 40 to 80% of an actively absorbed monosaccharide, 7.5 to 13% of an actively absorbed naturally occurring amino acid, and 0.5 to 10% of a citrate salt.
14. A composition as claimed in claim 13, wherein the monosaccharide is glucose.
15. A composition as claimed in claim 13, wherein the monosaccharide represents at least 65% of the composition.
16. A composition as claimed in claim 13, wherein the amino acid ii glycine.
17. A composition as claimed in any one of claims 13, 14 or 16, wherein the amino acid represents 8 to 12%
of the composition.
of the composition.
18. A composition as claimed in any one of claims 13, 14 or 16, additionally comprising 7 to 20% sidium chloride.
19. A composition as claimed in any of claims 13, 14 or 16, wherein the citrate salt represents 0.5 to 5%
of the composition.
of the composition.
20. A composition as claimed in claim 13, comprising 60 to 75% glucose, 8 to 12% glycine, 0.5 to 2% of a salt of citric acid, and 10 to 16% sodium chloride.
21. A composition as claimed in claim 13, additionally comprising an antibacterial agent.
22. A composition as claimed in claim 13, in aqueous solution.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1241876 | 1976-03-27 | ||
| GB1241776A GB1581826A (en) | 1976-03-27 | 1976-03-27 | Veterinary compositions for treating diarrhoea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1075157A true CA1075157A (en) | 1980-04-08 |
Family
ID=26249005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA274,190A Expired CA1075157A (en) | 1976-03-27 | 1977-03-17 | Veterinary composition containing mono-saccharide |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4164568A (en) |
| AU (1) | AU510209B2 (en) |
| CA (1) | CA1075157A (en) |
| DE (1) | DE2712786A1 (en) |
| DK (1) | DK166430B1 (en) |
| FR (1) | FR2345155A1 (en) |
| HK (1) | HK62984A (en) |
| IE (1) | IE45026B1 (en) |
| NL (1) | NL184666C (en) |
| NZ (1) | NZ183492A (en) |
| ZA (1) | ZA771409B (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA786856B (en) * | 1977-12-23 | 1979-11-28 | Beecham Group Ltd | Oral formulations for human use |
| DE3071229D1 (en) * | 1979-08-23 | 1985-12-19 | Beecham Group Plc | Anti-diarrhoea veterinary composition |
| FR2467599B1 (en) * | 1979-10-24 | 1983-07-29 | Agronomique Inst Nat Rech | NEW REHYDRATING COMPOSITIONS USEFUL IN PARTICULAR IN THE TREATMENT OF DIARRHEA IN CALVES |
| US4574085A (en) * | 1981-05-15 | 1986-03-04 | Baxter Travenol Laboratories, Inc. | Method for using dialysis solution containing glycerol |
| US4689319A (en) * | 1983-01-13 | 1987-08-25 | Colorado State University Research Foundation | Oral energy rich therapy for diarrhea in mammals |
| EP0114104B1 (en) * | 1983-01-13 | 1989-04-19 | Colorado State University Research Foundation | An oral energy-rich composition and solution for combatting diarrhea in mammals |
| DK454683D0 (en) * | 1983-10-03 | 1983-10-03 | Mogens Gjerloev | GAS ADMINISTRATIVE FOR TREATMENT OF ANIMALS AND USE OF ANIMALS |
| US5038396A (en) * | 1983-10-03 | 1991-08-06 | Mogens Gjerlov | Preparation for rehydrating monogastric animals, including new-born calves, pigs and human beings suffering from diarrhoea and use thereof |
| AU571011B2 (en) * | 1983-10-07 | 1988-03-31 | State Of Victoria, The | Treatment of neonatal calf diarrhoea |
| US4839347A (en) * | 1984-11-29 | 1989-06-13 | Techmix, Inc. | Composition for treating dehydration |
| FR2574295B1 (en) * | 1984-12-07 | 1988-02-26 | Rech Etu Therapeutiques | ZINC GLUCONATE MEDICINES USEFUL FOR THE TREATMENT OF HYPERPROLACTINEMIA |
| DE3684564D1 (en) * | 1985-11-18 | 1992-04-30 | Beecham Group Plc | VETERINAERE COMPOSITIONS. |
| FR2613228A1 (en) * | 1987-03-30 | 1988-10-07 | Agronomique Inst Nat Rech | Glucose-based rehydrating composition which is useful, in particular, in the treatment of diarrhoeal states and shock states in calves |
| IE81127B1 (en) * | 1989-02-07 | 2000-03-22 | Dimminaco Ag | Effervescent composition for oral rehydration |
| EP0653063A4 (en) * | 1992-07-27 | 1997-08-27 | Invitro International | In vitro test for dermal corrosive properties. |
| US5962733A (en) * | 1996-09-25 | 1999-10-05 | Vets Plus, Inc. | Glutamine containing electrolyte solution for calf scours |
| US6066341A (en) * | 1999-03-15 | 2000-05-23 | Farnam Companies, Inc. | Composition for the treatment of scours in calves |
| NZ518757A (en) * | 1999-10-19 | 2006-06-30 | Fuso Chemical Co | Agents for promoting fattening of animals and method of promoting fattening |
| US6365152B1 (en) | 2001-03-15 | 2002-04-02 | Bovine Health Products, Inc. | Scours treatment and method of making same |
| DK175877B1 (en) * | 2002-11-11 | 2005-05-09 | Pharmalett As | Preparations for use as a therapeutic agent |
| US20060039899A1 (en) * | 2004-08-23 | 2006-02-23 | Winn Robert T | Animal nutritional product that increases weight gain and reduces diarrhea morbidity, mortality and severity by stimulation of natural immune response, nutritional support of immune function and supplemental nutricines and probiotics |
| US20070160683A1 (en) | 2006-01-12 | 2007-07-12 | Land O'lakes Purina Feed Llc | Electrolyte supplement and method of use |
| US8529965B2 (en) * | 2007-07-09 | 2013-09-10 | Hill's Pet Nutrition, Inc. | Compositions and methods for altering stool quality in an animal |
| RU2444907C2 (en) * | 2007-07-09 | 2012-03-20 | Хилл'С Пет Ньютришн, Инк. | Fodder composition, kit and method for animal bowels action quality modification (versions) |
| RU2568136C2 (en) | 2007-07-09 | 2015-11-10 | Хилл`С Пет Ньютришн, Инк. | Compositions and methods for change in animal's stool quality |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2333950A (en) * | 1940-12-19 | 1943-11-09 | Gen Foods Corp | Therapeutic pectous product |
| US3080234A (en) * | 1960-12-06 | 1963-03-05 | Pfizer & Co C | Method of improving the efficiency of amino acid diets |
| US3362879A (en) * | 1965-01-11 | 1968-01-09 | Health Education Welfare Usa | Tyrosine tranquilizing compositions and methods of treatment |
| US3360434A (en) * | 1965-03-22 | 1967-12-26 | Udenfriend Sidney | Method for reducing blood pressure with phenylalanine derivatives |
| US3337404A (en) * | 1965-06-28 | 1967-08-22 | Merck & Co Inc | Effervescent potassium composition |
| US3743744A (en) * | 1972-02-29 | 1973-07-03 | Schering Corp | Means for inhibiting scours in piglets by administering a source of citrate ions |
| US3928574A (en) * | 1973-03-27 | 1975-12-23 | Univ Colorado State Res Found | Method and composition for treating diarrhea in mammals |
| US3898328A (en) * | 1973-12-03 | 1975-08-05 | Syntex Inc | Dry stable composition for the treatment of scours and dehydration |
| US4042684A (en) * | 1976-03-23 | 1977-08-16 | Annika Britt Kahm | Dietetic beverage |
-
1977
- 1977-03-03 NZ NZ183492A patent/NZ183492A/en unknown
- 1977-03-08 ZA ZA00771409A patent/ZA771409B/en unknown
- 1977-03-11 US US05/776,536 patent/US4164568A/en not_active Expired - Lifetime
- 1977-03-17 CA CA274,190A patent/CA1075157A/en not_active Expired
- 1977-03-18 FR FR7708150A patent/FR2345155A1/en active Granted
- 1977-03-23 DE DE19772712786 patent/DE2712786A1/en active Granted
- 1977-03-23 NL NLAANVRAGE7703128,A patent/NL184666C/en not_active IP Right Cessation
- 1977-03-24 AU AU23619/77A patent/AU510209B2/en not_active Expired
- 1977-03-25 IE IE635/77A patent/IE45026B1/en not_active IP Right Cessation
- 1977-03-25 DK DK134377A patent/DK166430B1/en not_active IP Right Cessation
-
1984
- 1984-08-09 HK HK629/84A patent/HK62984A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE2712786C2 (en) | 1989-05-18 |
| FR2345155A1 (en) | 1977-10-21 |
| FR2345155B1 (en) | 1980-02-01 |
| NL7703128A (en) | 1977-09-29 |
| HK62984A (en) | 1984-08-17 |
| NL184666B (en) | 1989-05-01 |
| ZA771409B (en) | 1978-02-22 |
| AU2361977A (en) | 1978-09-28 |
| NL184666C (en) | 1989-10-02 |
| DE2712786A1 (en) | 1977-09-29 |
| NZ183492A (en) | 1980-04-28 |
| IE45026L (en) | 1977-09-27 |
| AU510209B2 (en) | 1980-06-12 |
| US4164568A (en) | 1979-08-14 |
| DK134377A (en) | 1977-09-28 |
| DK166430B1 (en) | 1993-05-24 |
| IE45026B1 (en) | 1982-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1075157A (en) | Veterinary composition containing mono-saccharide | |
| US5008248A (en) | Veterinary compositions for the treatment of scours and dehydration | |
| EP0025269B1 (en) | Anti-diarrhoea veterinary composition | |
| Cummins et al. | Safety evaluation of selenium sulfide antidandruff shampoos | |
| Herman et al. | Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (±)-1, 2-bis (3, 5-dioxopiperazinyl-1-yl) propane (ICRF-187) | |
| Satoh et al. | Involvement of cardiac metallothionein in prevention of adriamycin induced lipid peroxidation in the heart | |
| US7416742B2 (en) | Methods and compositions for controlling microorganism populations in the digestive system of animals | |
| KR910004185A (en) | Compounds and their use for reversing multidrug resistance of cancer cells against cytotoxin agents | |
| MY102740A (en) | Anti-diarrhea compositions. | |
| NZ209645A (en) | Veterinary compositions containing glucose,sodium ions,and chloride ions | |
| DE69833937T2 (en) | USE OF ZINC HYALURONATE AGAINST STOMACH | |
| Brownie et al. | Teratogenic effect of calcium edetate (CaEDTA) in rats and the protective effect of zinc | |
| US4839347A (en) | Composition for treating dehydration | |
| SPAETH et al. | Treatment of Trichinosis: Case Report | |
| US4591503A (en) | Composition for improved absorption of 2A cations and gold comprising yeast or Lactobacillus | |
| GB1581826A (en) | Veterinary compositions for treating diarrhoea | |
| EP0059057A1 (en) | Treatment of diarrhoea | |
| Barlow et al. | STUDIES ON THE PHARMACOLOGY OF SULFAPYRIDINE AND SULFATHIAZOLE: THE ABSORPTION OF THE FREE ACID, THE SODIUM SALT AND THE GLUCOSIDE FROM THE ALIMENTARY TRACT | |
| Henness et al. | Clinical comparison of cefadroxil and cephalexin in uncomplicated urinary tract infection | |
| Raphael et al. | Plasma concentration of gentamicin in turtles | |
| JPS62126130A (en) | Medicinal composition for animals | |
| Hansen et al. | The effect of Cu on gill and esophagus lipid metabolism in the rainbow trout Oncorhynchus mykiss | |
| Itokawa et al. | Toxicity of polychlorinated biphenyls increased with simultaneous ingestion of alkylbenzene sulfonic acid salt | |
| DE3104282C2 (en) | ||
| McNaught et al. | Effects of Sulfanilamide, Phenothiazine and Thionol in Experimental Trichinosis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |